We are a small publicly traded life science enterprise invested in commercial innovations in phytomedical discoveries of small molecule antivirals and have a significant footprint in human nutrition including the development of an RUTF for SAM and an Enteral Formula targeting the long term effects of COVID 19.
AREV Global Life Sciences Corp. (AREV) is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. Our strategy is dedicated to generating revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic comorbidities.
We are invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and have a significant footprint in human nutrition including the development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long term effects of COVID-19. Through our Scientific Advisory Board (SAB) and strategic collaborations with Voynich Biosciences and Oyagen, we are connected to the Linus Pauling Institute at Oregon State University (OSU) and with the Institute of Human Virology. AREV is working with scientists at Voynich and Oyagen to serve as preclinical discovery partners for our REV inhibitor. Our SAB is reflective of industry leaders and academic collaborations.
AREV is dedicated to designing and delivering innovation in nutritional therapeutics and rational drug design, driven by molecular epidemiology. AREV’s business model is driven by leveraging its core competency of extraction to produce ingredients and compounds for its pipeline of products.
We strive to innovate human and animal health solutions through phytomedicinalization and commercialization of unique botanicals and select marine species while we grow through licensing relationships, joint ventures, and acquisitions.
AREV is driven by a commitment to offering novel therapeutic solutions and innovations in global public health applications that address the clinical needs of vulnerable key populations affected by pandemic diseases.
AREV believes in equitable collaborations, including mutually advantageous relationships with relevant industry partnerships, academia institutions, and civil society. AREV believes in good corporate practice: accountability on all levels, fiscal responsibility, a commitment to shareholders, integrity, and transparency.
AREV stands in alliance with International declarations such as The Right to Health (a collaboration of the World Health Organization and Office of the United Nations High Commissioners for Human Rights), in our commitment to global citizenship by addressing issues that have a dramatic impact on infectious diseases and access to treatments in resource poor settings.
AREV is committed to ethical sourcing at all levels of our product development and research.
AREV is committed to empowerment of our staff, of the communities we work in, and to the life sciences sector.
AREV is committed to fair workplace culture. We believe it is a delicate blend of an organisation's leadership, values, traditions, beliefs, interactions, behaviours and attitudes that contribute to the emotional and relational environment of your workplace.
AREV is committed to fair practice in addressing racial and gender disparities in access to essential medicine.
AREV is committed to timely compliance with all regulatory obligations.
Mr. Withrow is a successful natural products and technology entrepreneur with over 25 years experience in public markets. He has an extensive business network throughout the Americas and Pacific Rim, and his experience in international trade and regulatory compliance have been essential to the companies that he has structured and led.
With a background of starting many agricultural-type companies and helping them to grow, he has worked with and led companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. Mr. Withrow has expanded his company, CanViet Enterprises Inc., internationally and met the opportunities where they resided. He was instrumental in securing millions of dollars in public and private investments to fund the working capital requirements of his high-growth companies. In addition, Mr. Withrow has also held senior advisory positions for a number of companies.
Mr. Withrow is the founder of the company and has been the Chairman of the Board of AREV since inception. He has also served as the President, CEO of Abattis Bioceuticals Corp. from 2011 – 2015. Abattis Bioceuticals Corp. a specialty cannabis company producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in the pharmaceuticals, nutraceuticals, cosmetics, and animal nutrition markets.
He also served in directorships/management positions with North American BioExtracts Inc. (2010-2015), with Canadian Pacific Phytoplankton Ltd. and Canadian Pacific Algae Inc. (2008-2010) and with BFuel Canada (2006-2007).
Mr. Kevin Phelps is a successful biotech and general business professional with over 30 years’ experience in business assessment, business development, commercialization, operations, mergers/acquisitions, capital formation, franchising and licensing. Kevin has been a member of numerous executive teams as CEO, CFO and VP Business Development. He has successfully managed and sold several entrepreneurial businesses and raised millions of dollars in early and growth stage capital.
Currently, Mr. Phelps is Chief Executive Officer and President of Immune Therapeutics, Inc., an OTC listed (IMUN) bio-pharmaceutical company. He was originally recruited to Immune in November 2018 as a Director. In April 2020 he was voted in as President and CEO.
Kevin began his career as a CPA with Price Waterhouse Coopers specializing in services to emerging growth companies. In 1987 he was recruited to the Eastman Kodak Company and as part of an executive team successfully executed the spinout of the Bio Products Division into Genencor International, Inc., an international industrial bio-chemicals company. Mr. Phelps served as Chief Financial Officer and VP of Business Development. In those capacities he was directly responsible for executing the formation strategy of the new Company and later the acquisition of two European chemical company competitors.
Following Genencor, Mr. Phelps joined Trillium Group, a regional private equity firm, as a partner, during which time he underwrote and developed a portfolio of small growth companies including several in the drug development and medical device sectors. While there he served on behalf of the firm as CFO of Vaccinex, Inc., a vaccine development company and Chairman of AccuMed, Inc., a medical device company.
Mr. Phelps graduated from the University of Notre Dame with a degree in Accounting. He is a former CPA and has been active in Upstate New York venture capital community. In addition to the AREV Board, he currently serves on the Boards of OyaGen, Inc. (Chairman), Immune Therapeutics, Inc., and Rochester Friendly Senior Services (Treasurer).
Ms. Greenslade has worked as a Corporate Secretary and Director for several companies in the mining, biotech and IT industries and is constantly updating her business training.
She is responsible for the creation and regulation of the Company’s corporate governance structures, policies and mechanisms; corporate communication, conduct and regulatory compliance in both Canada and the United States; Board and shareholder meetings and communication; office and personnel management; creation and administration of company policies and procedures; and implementation of corporate-wide management and document retention systems.
Ms. Greenslade has over 15 years of corporate secretarial, corporate governance, and securities regulation experience with a focus on the nutraceutical and mining sector in Canada and Mexico. She has served in several senior management and executive roles for companies listed on the Toronto Stock Exchange, TSX Venture Exchange and Canadian Stock Exchange.
During her career, she has been involved in numerous transactions and financings, and has led the evaluation, design, implementation and monitoring of governance programs for several junior mining companies.
Ms. Greenslade graduated from Simon Fraser University, British Columbia with a Bachelor of Arts in Communication and further attended BCIT to complete an associate certificate in Graphic Design.
Michael Frank Phillet is on the board of First West Properties Ltd. and APA Bioceuticals, Inc. and Partner at Phillet & Mclennan Chartered Accountants. He holds a BA, CA and CPA designation. He has been in public practice for 40 years.
Chad S. Johnson, Esq., is a Harvard-trained corporate, legislative, and regulatory attorney with significant experience in advising health and biotechnology companies and pursuing entrepreneurial ventures. After clerking for a federal judge, Chad joined top law firm Skadden, Arps, Slate, Meagher & Flom LLP in its Washington, DC office where he focused on financial institution regulatory law and substantial pro bono advocacy on behalf of political, civil rights, and poverty-mitigation and other civic organizations. Leaving the firm after several years to work on a presidential campaign as deputy national director of business leader outreach, he is an active member of the District of Columbia Bar and the Bar of the U.S. Supreme Court. Chad works as a business leader, board member, and legal counsel for North American and European health-related, drug-development, and biotechnology companies and non-profit organizations, with a focus on entrepreneurial ventures in biotechnology and pathogen-related treatment and mitigation. He is a member of the IAS and the Infectious Disease Society of America and has attended numerous scientific conferences internationally. Chad remains active in the Harvard College and Harvard Law School alumni associations. Originally from Kansas, Chad has lived and worked in Washington, DC and/or the DC metro area for more than 25 years.